|

carboplatin Clinical Trials

320 actively recruiting trials across 72 locations

Also known as: Background Platinum-based Chemotherapy, Blastocarb, Bobei, C6H12N2O4Pt, CARBO +46 more

Pipeline

Early 1: 5Phase 1: 29Phase 2: 144Phase 3: 76Phase 4: 4Phase 1/2: 44Phase 2/3: 10

Top Sponsors

  • Merck Sharp & Dohme LLC19
  • National Cancer Institute (NCI)15
  • AstraZeneca15
  • Memorial Sloan Kettering Cancer Center8
  • University of Chicago7

Indications

  • Cancer320
  • Lung Cancer138
  • Breast Cancer48
  • Non Small Cell Lung Cancer41
  • Ovarian Cancer15

Other121 trials

A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)
Phase 1/2
A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer
Phase 1/2
A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
Phase 2/3
A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors
Phase 1/2
A Phase I/II Study of LM-2417 in Subjects With Advanced Solid Tumours
Phase 1/2
A Phase III Study of KN026 in Combination With HB1801 ± Carboplatin as Neoadjuvant Treatment for Early or Locally Advanced HER2-Positive Breast Cancer
Phase 3
A Phase Ib Study of JMKX001899 in Combination With Other Therapies in Advanced NSCLC Harboring KRAS G12C Mutation
Phase 1
A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors
Phase 1/2
A Prospective, Open, Multicenter Single-arm Clinical Studie of Docetaxel, Carboplatin Combined With Inetetamab and Pyrotinib in the Treatment of Local-advanced HER2-positive Breast Cancer
N/A
A Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer
Phase 1
A Safety and Efficacy Study of Bevacizumab, Paclitaxel, Carboplatin Compared to Avastin® in Non-Small Cell Lung Cancer
Phase 3
A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cancer)
Phase 2
A Study for the Adjuvant Treatment of Breast Cancer
Phase 4
A Study for the Neoadjuvant Treatment of Breast Cancer
Phase 4
A Study of Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoadjuvant Therapy and Biomarker Analysis in Limited-stage Small Cell Lung Cancer
Phase 2
A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC
Phase 3
A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)
Phase 2
A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer
Phase 2
A Study of MHB036C Combined With Anti-tumor Therapies in Patients With Advanced Lung Cancer
Phase 1/2
A Study of Pembrolizumab (MK-3475) Plus Platinum and Gemcitabine as First Line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (PIPER)
Phase 2
A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection.
Phase 3
A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma
Phase 3
A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC
Phase 1/2
A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer
Phase 2
A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer
Phase 3
A Study of SKB518 in Patients With Lung Cancer
Phase 2
A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLC
Phase 1
A Study on the Efficacy of Atezolizumab Combined with Chemotherapy
A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer
Phase 2
A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study)
Phase 3
A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC
Phase 3
A Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients
Phase 2
A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor
Phase 1/2
A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma
Phase 3
AB122 Platform Study
Phase 1
AK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung Cancer
Phase 2
AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer
Phase 1/2
AK129 Combination Therapy for Advanced Solid Tumors
Phase 1/2
Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer
Phase 2
Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)
Phase 2
Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung Cancer
N/A
Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung Cancer
Phase 2
Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC).
Phase 2
BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer
Phase 2/3
Cadonilimab (AK104) Plus Chemotherapy as First-line Treatment in Non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients With Programmed Cell Death Ligand 1 (PD-L1) Negative
Phase 2
Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer
Phase 2
Chemoradiotherapy in Elderly Patients With Oesophagus Cancer
Phase 1/2
Clinical Efficacy Study of PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Advanced Endometrial Cancer
Phase 2
Cryoablation in Combination (or Not) With Pembrolizumab and Pemetrexed-carboplatin in 1st-line Treatment for Patients With Metastatic Lung Adenocarcinoma
Phase 3
DUMAS: Neo-Adjuvant Immunotherapy for Pancoast Tumors
Phase 2
DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7)
Phase 1/2
EC-THP Versus TCbHP in HER2-positive Lymph Node Positive Early Breast Cancer
Phase 3
ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer
Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation
Phase 1
Electrochemotherapy With Carboplatinum Plus Bleomycin Versus Bleomycin Alone in Vulvar Cancer
Phase 2
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors
Phase 1/2
Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCC
Phase 3
First-line CBDCA/PTX/LEN/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas (Artemis)
Phase 2
Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer
Phase 2
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
Phase 2
High Risk Neuroblastoma Study 1.8 of SIOP-Europe (SIOPEN)
Phase 3
IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer
Phase 2
IN10018 Combination Therapy in Treatment-naïve ES-SCLC
Phase 1/2
Impact of Fat-free Mass in the Carboplatin Calculated Dose and Chemotherapeutic Toxicity in Patients With Advanced NSCLC
Induction Chemotherapy Followed by Standard Therapy in Cervical Cancer With Aortic Lymph Node Spread
Phase 3
Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer
Phase 2
JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation
Phase 3
Modified CV Regimen in Optic Pathway Glioma
Phase 2
Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC
Phase 2
Neoadjuvant Chemotherapy Followed by Chemoradiation Versus Chemoradiation for Stage IIIC Cervical Cancer Patients: A Randomized Phase III Trial
Phase 3
Neoadjuvant IBI308, Bevacizumab, Plus Pemetrexed and Carboplatin Followed by Surgery in Unresectable Stage III NSCLC
Phase 2
Neoadjuvant Immunotherapy Combined With Chemotherapy Sequenced With Endoscopic Resection for Esophageal Cancer (Endosurgery-02)
Phase 1
Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC
Phase 2
Neoadjuvant Pembrolizumab and Carboplatin Plus Paclitaxel for Stage I Triple-negative Breast Cancer
Phase 2
Neoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer
Phase 2
Neoadjuvant Study of HIFU With or Without PD-1 Inhibitors Followed by Abraxane Plus Carboplatin in Triple-Negative Breast Cancer.
Phase 2
Neoadjuvant Therapy of Sintilimab Combined With Chemotherapy for Resectable Squamous Cell NSCLC（neoSCORE Ⅱ）
Phase 3
Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast Cancer
Phase 2
Neoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Small-Cell Lung Cancer (NSCLC)
Phase 2
Neoadjuvant Upper Tract Invasive Cancer Trial (NAUTICAL)
Phase 3
Nimotuzumab Combined With Toripalimab and Chemotherapy for Locally Advanced Tonsillar Cancer
Phase 2
Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer
Phase 3
Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer
Phase 2
Optimization of Treatment Strategy for Unresectable cN3 Esophageal Squamous Cell Carcinoma
Phase 2
Organoid-based Functional Precision Therapy for Advanced Breast Cancer
Phase 2
PALACE: Cemiplimab Trial According to ctDNA Levels
Phase 2
Pathological Response After Neoadjuvant Treatment on NSCLC
Pembrolizumab, Carboplatin and Cabazitaxel in Aggressive Metastatic Castration Resistant Prostate Cancer (PEAPOD_FOS)
Phase 2
Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC
Phase 2
Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma
Phase 4
Perioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung Cancer
Phase 2
Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI
Phase 1/2
Phase 1b/2 Study of LDRT in Combination With AK104 Plus Chemotherapy as First-line Treatment for ES-SCLC
Phase 1/2
Phase II Study of Ivonescimab and Cadonilimab in Combination with Chemotherapy in Patients with ES-SCLC
Phase 2
Phase II Study on Neoadjuvant Therapy of AK104 Combined With Nab-paclitaxel/Carboplatin in Fertility Preserving Surgery
Phase 2
Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01）
Phase 3
Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation
Early 1
Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes
Phase 3
Posaconazole Plus PD-1 Inhibitors and Chemotherapy vs PD-1 Inhibitors and Chemotherapy in Neoadjuvant Therapy for Triple Negative Breast Cancer
Phase 2
ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer
Phase 3
Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer
Phase 2
SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC
Phase 2
SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer.
Phase 2
Safety and Efficacy of Neoadjuvant Immunochemotherapy in Elderly Patients With Resectable Esophageal Cancer
Phase 2
Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer
Phase 1/2
Study of Low-Dose Radiotherapy Concurrent Chemotherapy With Serplulimab for Patients With ES-SCLC
Phase 2
Study of Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-stage Small Cell Lung Cancer
Phase 2
Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma
Phase 3
Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.
Phase 3
Study of ZG005 in Combination With Paclitaxel＋Platinum-based ± Bevacizumab in Patients With Advanced Cervical Carcinoma
Phase 1/2
TC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors
Phase 3
TC or BEP in Treating Patients With Ovarian Malignant Sex Cord-Stromal Tumors
Phase 3
TCb vs EC-T in High Risk ER+/HER2- Breast Cancer
Phase 3
TGF-β And PDL-1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemoradiation TheRapY
N/A
TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer
Phase 3
Therapeutic Strategy Guided by PET-TDM for Patients With Seminoma
Phase 2
Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer
Phase 2
Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer
Phase 2
Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy
Phase 2
Using ctDNA to Determine Therapies for Lung Cancer
Phase 2
Utility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery
Phase 3

Birmingham, Alabama24 trials

A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)

Central Alabama Research ( Site 0108)

Phase 3
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT)

Children's Hospital of Alabama

Phase 3
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

Local Institution - 0347

Phase 3
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

Children's Hospital of Alabama

Phase 2
A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

University of Alabama -Birmingham

Phase 1/2
A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT

Children's Hospital of Alabama

Phase 2
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors

University of Alabama at Birmingham

Phase 1
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.

University of Alabama at Birmingham (UAB) Hospital /ID# 274793

Phase 2
A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma

Children's Hospital of Alabama

Phase 1/2
A Study to Give Treatment Inside the Eye to Treat Retinoblastoma

Children's Hospital of Alabama

Phase 2
A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS

Research Site

Phase 3
A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer

University of Alabama at Birmingham

Phase 3
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors

Children's Hospital of Alabama

Phase 3
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

University of Alabama at Birmingham Cancer Center

Phase 3
DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC

University of Alabama at Birmingham

Phase 2
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

Children's Hospital of Alabama

Phase 3
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer

University of Alabama at Birmingham Cancer Center

Phase 3
Newly Diagnosed Stage III/IV Ovarian Cancer, Neoadjuvant Carbo/Taxol/Pembro, Maintenance Olaparib/Pembro

O'Neal Comprehensive Cancer Center at UAB

Phase 2
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

University of Alabama at Birmingham Cancer Center

Phase 3
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

University of Alabama at Birmingham

Phase 1/2
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

University of Alabama at Birmingham Cancer Center

Phase 2
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Children's Hospital of Alabama

Phase 3
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma

University of Alabama at Birmingham Cancer Center

Phase 3
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

University of Alabama at Birmingham Cancer Center

Phase 3

Tucson, Arizona9 trials

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

Research Site

Phase 3
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

Southern Arizona VA Health Care System

Phase 3
Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery

University of Arizona Cancer Center-Orange Grove Campus

Phase 2
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

Research Site

Phase 3
Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) With the Contrast Agent Iohexol

University of Arizona Cancer Center-Orange Grove Campus

Phase 1
Study of Novel Treatment Combinations in Patients With Lung Cancer

Arizona Oncology Associates,Substudy-01

Phase 2
Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

University of Arizona Cancer Center

Phase 1/2
Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread

The University of Arizona Cancer Center-North Campus

Phase 2
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

Banner University Medical Center - Tucson

Phase 2

Chicago, Illinois9 trials

A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma

University of Chicago (Data Collection Only)

Phase 2
A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer

University of Chicago Comprehensive Cancer Center

Phase 2
Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer

University of Illinois Medical Center

Phase 2
Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)

University of Chicago Medicine

Phase 2
Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer

Northwestern University

Phase 2
Personalized, Adaptive Treatment for Locally Advanced Head and Neck Cancer

University of Chicago Medicine Comprehensive Cancer Center

Phase 1
Response-Adaptive Treatment in Untreated Locoregional HPV-Negative Head and Neck Cancer

The University of Chicago

Phase 2
TheraT® Vectors (Vaccines) Combined With Chemotherapy to Treat HPV16 Head and Neck Cancers

University of Chicago

Phase 1/2
Toripalimab in Combination With Standard Treatment for Human Papillomavirus (HPV) Positive Throat Cancer

The University of Chicago Medicine Comprehensive Cancer Center

Phase 2

Anchorage, Alaska8 trials

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

Alaska Oncology and Hematology

Phase 3
A Study of Sigvotatug Vedotin in Advanced Solid Tumors

Alaska Oncology and Hematology

Phase 1
A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

Alaska Oncology and Hematology

Phase 3
A Study to Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

Alaska Oncology and Hematology

Phase 2/3
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)

Alaska Oncology and Hematology

Phase 2
Carboplatin Chemotherapy Before Surgery for People With High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation

Anchorage Associates in Radiation Medicine

Phase 2
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

Alaska Oncology and Hematology, LLC

Phase 2/3
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Anchorage Associates in Radiation Medicine

Phase 3

Los Angeles, California8 trials

A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer

USC Norris Comprehensive Cancer Center /ID# 275343

Phase 2/3
Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer

Cedars-Sinai Medical Center

Phase 2
Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer

UCLA / Jonsson Comprehensive Cancer Center

Phase 1/2
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

Research Site

Phase 2
Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC

Research Facility

Phase 1
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors

Research Site

Phase 2
Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma

Los Angeles General Medical Center

Phase 1/2
Volrustomig Priming Regimens Exploratory Phase II Platform Study

Research Site

Phase 2

Houston, Texas8 trials

Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Nasal NK Cell Lymphoma

MD Anderson Cancer Center

Phase 2
Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer

Harris Health System - Smith Clinic

Phase 2
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery

MD Anderson Cancer Centre

N/A
Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA)

M D Anderson Cancer Center

Phase 2
Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy

M D Anderson Cancer Center

Phase 2
NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer

M D Anderson Cancer Center

Phase 1
Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer

MD Anderson Cancer Center

Phase 2
Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer

M D Anderson Cancer Center

Phase 1

Duarte, California7 trials

A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation

City of Hope National Medical Center

Phase 1/2
A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases

City of Hope

Phase 3
A Study of ASP3082 in Adults With Advanced Solid Tumors

City of Hope National Medical Center

Phase 1
A Study of ZL-1310 in Subjects With Small Cell Lung Cancer

Zai Lab Site 2005

Phase 1
Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer

City of Hope

Phase 1
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors

Research Site

Phase 1/2
Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC

Research Site

Phase 1

Gilbert, Arizona5 trials

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

Banner MD Anderson Cancer Center ( Site 0066)

Phase 3
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

Banner MD Anderson Cancer Center ( Site 0181)

Phase 3
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)

Banner MD Anderson Cancer Center ( Site 0001)

Phase 1/2
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy

Local Institution - 0167

Phase 2/3
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

Banner MD Anderson Cancer Center

Phase 1/2

La Jolla, California5 trials

A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer

University of California at San Diego Moores Cancer Center

Phase 1/2
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

University of California at San Diego

Phase 2
Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment

Research Site

Phase 3
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

University of California, San Diego

Phase 2
Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Moores Cancer Center /ID# 267782

Phase 2/3

Basking Ridge, New Jersey5 trials

A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer

Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)

Phase 1
A Study of Decreasing Radiation Therapy and Chemotherapy in People With Head and Neck Cancer

Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities)

Phase 2
A Study of Reduced Radiation Therapy and Standard-of-Care Chemotherapy in People With HPV-Positive Throat Cancer

Memorial Sloan Kettering Cancer Center at Basking Ridge (Limited Protocol Activities)

Phase 2
A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer

Memorial Sloan Kettering Basking Ridge (All protocol activities)

Early 1
Adding Certolizumab to Chemotherapy + Nivolumab in People Who Have Lung Cancer That Can Be Treated With Surgery

Memorial Sloan Kettering at Basking Ridge Limited Protocol Activities

Phase 2

Daphne, Alabama4 trials

A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC

Southern Cancer Care

Phase 2
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

Research Site

Phase 3
A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).

Southern Cancer Center, PC

Phase 3
Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)

Southern Cancer Center (SCC) ( Site 8004)

Phase 2

Mobile, Alabama4 trials

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC

Research Site

Phase 3
A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma

USA Health Strada Patient Care Center

Phase 2
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)

USA Mitchell Cancer Institute ( Site 0090)

Phase 3
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

University of South Alabama, Mitchell Cancer Institute ( Site 6033)

Phase 3

Phoenix, Arizona4 trials

A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

Research Site

Phase 1/2
Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer

Mayo Clinic Hospital in Arizona

Phase 3
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma

Research Site

Phase 3
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

USOR HonorHealth

Phase 1/2

Little Rock, Arkansas4 trials

A Study of Toripalimab in Combination With Cisplatin and Gemcitabine in Participants With Recurrent Metastatic Nasopharyngeal Cancer

University of Arkansas for Medical Sciences

Phase 4
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

UAMS Winthrop P. Rockefeller Cancer Institute ( Site 0060)

Phase 3
Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

Research Site

Phase 2
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

CARTI Cancer Center ( Site 0006)

Phase 3

Fullerton, California4 trials

A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors

Providence Medical Foundation

Phase 1/2
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

Providence St Jude Medical Center

Phase 3
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma

Research Site

Phase 2/3
Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

Providence - St. Jude Medical Center /ID# 271414

Phase 1/2

Boston, Massachusetts4 trials

Folfox+Irinotecan+Chemort In Esophageal Cancer

Massachusetts General Hospital

Phase 2
LuCarbo - a Study of 177Lu-PSMA-617 Plus Carboplatin in Metastatic Castrate-resistant Prostate Cancer

Beth Israel Deaconess Medical Center

Phase 1
Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC

Brigham and Women's Hospital

Phase 2
Toripalimab With Chemotherapy for Sinus Cancer

Brigham and Women's Hospital

Phase 2

Columbus, Ohio4 trials

Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal Cancer

Ohio State University Comprehensive Cancer Center

Phase 2
Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer

Ohio State University Comprehensive Cancer Center

Early 1
Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma

Ohio State University Comprehensive Cancer Center

Phase 2
Testing the Addition of Cemiplimab (REGN2810) to Chemotherapy Treatment Given Prior to Surgery in Patients With Sinonasal Squamous Cell Carcinoma

Ohio State University Comprehensive Cancer Center LAO

Phase 2

Fayetteville, Arkansas3 trials

A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Research Site

Phase 3
Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial

Highlands Oncology Group - Fayetteville

Phase 3
Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body

Highlands Oncology Group - Fayetteville

Phase 3

Sacramento, California3 trials

Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell Lymphoma

University of California Davis Comprehensive Cancer Center

Phase 2
Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers

UC Davis Cancer Center (Data Collection Only)

Phase 2
Testing the Addition of Chemotherapy or Chemo-Immunotherapy to the Usual Surgery for Advanced Head and Neck Cancer

Sutter Medical Center Sacramento

Phase 2

New York, New York3 trials

A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation

Memorial Sloan Kettering Cancer Center

Phase 2
N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma

Memorial Sloan Kettering Cancer Center

Phase 2
Neoadjuvant Dupilumab, Pembrolizumab, Paclitaxel, and Carboplatin in Locally Advanced Triple Negative Breast Cancer

Mount Sinai Health System

Early 1

Philadelphia, Pennsylvania3 trials

Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance

Abramson Cancer Center of the University of Pennsylvania

Phase 2
Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer

Fox Chase Cancer Center

Phase 2
Gemcitabine and Carboplatin After Progression on Enfortumab Vedotin and Pembrolizumab in Advanced/Metastatic Urothelial Carcinoma

Fox Chase Cancer Center

Phase 2

Pittsburgh, Pennsylvania3 trials

CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer

Magee-Womens Research Institute / UPMC Magee Womens Hospital

Phase 1
Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC

UPMC Hillman Cancer Center

Phase 2
Transoral Surgical Resection Followed by De-escalated Adjuvant IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer

UPMC Hillman Cancer Center

Phase 2

Nashville, Tennessee3 trials

Neoadjuvant Darolutamide Alone or in Combination With Standard Therapy for Stage II-IIIA, AR+, TNBC

Vanderbilt University/Ingram Cancer Center

Phase 2
Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation

Vanderbilt University/Ingram Cancer Center

Phase 1/2
Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer

Vanderbilt University/Ingram Cancer Center

Phase 1/2

Seattle, Washington3 trials

A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negative Breast Cancer

Fred Hutch/University of Washington Cancer Consortium

Phase 2
Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer

Fred Hutch/University of Washington Cancer Consortium

Phase 2
Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study

Fred Hutch/University of Washington Cancer Consortium

Phase 2

Huntsville, Alabama2 trials

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Clearview Cancer Institute

Phase 3
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

Clearview Cancer Institute

Phase 3

Scottsdale, Arizona2 trials

A Study of LY4170156 in Participants With Selected Advanced Solid Tumors

HonorHealth

Phase 1
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas

HonorHealth Research Institute

Phase 1

Beverly Hills, California2 trials

A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma

Precision NextGen Oncology and Research Center

Phase 2
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Precision NextGen Oncology

Phase 1/2

Irvine, California2 trials

A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan Versus Standard of Care in the Treatment of Advanced Urothelial Cancer

UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care

Phase 3
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

Local Institution - 0279

Phase 2/3

Orange, California2 trials

A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation

D3 Bio Investigative Site 0402

Phase 1/2
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

UC Irvine Health/Chao Family Comprehensive Cancer Center

Phase 2

Santa Monica, California2 trials

A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

UCLA

Phase 1
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

UCLA Hematology/Oncology - Parkside ( Site 0021)

Phase 2

Stanford, California2 trials

A Study of GSK5764227 in Participants With. Advanced Solid Tumors (EMBOLD PanTumor-101)

GSK Investigational Site

Phase 1
Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC

Stanford University

Phase 3

Aurora, Colorado2 trials

A Study of ZN-c3 in Patients With Ovarian Cancer

Site 0264

Phase 1
Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)

Call for Information (Investigational Site 2041)

Phase 1/2

New Haven, Connecticut2 trials

A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer

Yale University School of Medicine /ID# 278181

Phase 2
Study of AVZO-021 in Patients With Advanced Solid Tumors

Yale Cancer Center

Phase 1/2

Washington D.C., District of Columbia2 trials

Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer

Johns Hopkins University: Sibley Memorial Hospital

Phase 2
Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy

Lombardi Comprehensive Cancer Center, Georgetown University

Phase 2

Tampa, Florida2 trials

A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001)

Moffitt Cancer Center ( Site 0261)

Phase 1
Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC

Moffitt Cancer Center

Phase 2

Lexington, Kentucky2 trials

A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)

University of Kentucky ( Site 0019)

Phase 2
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

University of Kentucky Chandler Medical Center

Phase 1

Baltimore, Maryland2 trials

PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 2
Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Johns Hopkins Medicine SKCCC

Phase 1/2

Winston-Salem, North Carolina2 trials

First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients

Wake Forest Baptist Health Sciences

Phase 2
Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy

Wake Forest Baptist Comprehensive Cancer Center

Phase 2

Hot Springs, Arkansas1 trial

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

Local Institution - 0303

Phase 2/3

Jonesboro, Arkansas1 trial

A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

Saint Bernards Medical Center

Phase 3

Springdale, Arkansas1 trial

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

Highlands Oncology Group

Phase 3

Bakersfield, California1 trial

AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).

Comprehensive Blood and Cancer Center

Phase 1

Buena Park, California1 trial

Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer

Keck Medicine of USC Buena Park

Phase 2

Carmichael, California1 trial

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

Mercy Cancer Center - Carmichael

Phase 3

Dublin, California1 trial

Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal Cancer

Kaiser Permanente Dublin

Phase 2

Long Beach, California1 trial

A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer

Oncology Institute

Phase 2

Newport Beach, California1 trial

A Study to Learn More About How Well Sevabertinib (BAY 2927088) Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)

Patty & George Hoag Cancer Center

Phase 3

Oakland, California1 trial

Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)

Kaiser Permanente - Oakland ( Site 0054)

Phase 3

Palo Alto, California1 trial

Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma

Lucille Packard Children's Hospital Stanford

Phase 2

San Diego, California1 trial

ROCKIF Trial: Re-sensitization of Carboplatin-resistant Ovarian Cancer With Kinase Inhibition of FAK

University of California San Diego

Phase 1/2

West Los Angeles, California1 trial

Carboplatin or Olaparib for BRcA Deficient Prostate Cancer

VA Greater Los Angeles Healthcare System, West Los Angeles, CA

Phase 2

Clermont, Florida1 trial

KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)

Clermont Oncology Center ( Site 0041)

Phase 2

Miami, Florida1 trial

DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers

University of Miami

Phase 1

Miami Beach, Florida1 trial

A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)

Mount Sinai Comprehensive Cancer Center ( Site 6000)

Phase 3

Orlando, Florida1 trial

Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer

Advent Health

Phase 3

Maywood, Illinois1 trial

Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer

Loyola University Medical Center

Phase 2

Indianapolis, Indiana1 trial

Study of Pembrolizumab, Carboplatin, Paclitaxel, and Radiation for the Treatment of Early-Stage Anal Cancer

Indiana University Melvin and Bren Simon Comprehensive Cancer Center

Phase 2

Fairway, Kansas1 trial

Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC

The University of Kansas Cancer Center - Clinical Research Center

Phase 2

Louisville, Kentucky1 trial

A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)

The University of Louisville, James Graham Brown Cancer Center ( Site 0009)

Phase 1/2

Bethesda, Maryland1 trial

Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial

National Cancer Institute Developmental Therapeutics Clinic

Phase 2

Ann Arbor, Michigan1 trial

Personalized Neck Radiation Therapy Directed by Sentinel Lymph Node Biopsy for the Treatment of Oral Cavity Squamous Cell Carcinoma, PRECEDENT Trial

University of Michigan Comprehensive Cancer Center

Phase 2

Mankato, Minnesota1 trial

Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

Mayo Clinic Health Systems-Mankato

Phase 2

Minneapolis, Minnesota1 trial

Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma

Masonic Cancer Center, University of Minnesota

Phase 2

Elizabeth, New Jersey1 trial

ATATcH Alternating Treatment Plans for Advanced Cancer

Trinitas Hospital and Comprehensive Cancer Center

Phase 2

Hackensack, New Jersey1 trial

A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors

John Theurer Cancer Center at Hackensack University Medical Center

Phase 1/2

Paramus, New Jersey1 trial

A Study of V940/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)

Valley Health Systems - Ridgewood Campus ( Site 0010)

Phase 2

Teaneck, New Jersey1 trial

A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies

Holy Name Medical Center /ID# 279017

Phase 2

Buffalo, New York1 trial

Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer

Roswell Park Cancer Institute

Phase 2

Syracuse, New York1 trial

Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC

SUNY Upstate Medical University

Early 1

Valhalla, New York1 trial

Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL

New York Medical College

Phase 2

Charleston, South Carolina1 trial

Anthracycline-Free Neoadjuvant Chemoimmunotherapy for Triple Negative Breast Cancer Patients

Medical University of South Carolina

Phase 2

Memphis, Tennessee1 trial

Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors

St. Jude Children's Research Hospital

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.